Seminars in Radiation Oncology
Volume 18, Issue 3 , Pages 168-174 , July 2008

Economic Analysis of Health Care Interventions

  • Andre Konski, MD, MBA, MA, FACR

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Andre Konski, MD, MBA, MA, FACR, Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

References 

  1. Drummond M. Australian guidelines for cost-effectiveness studies of pharmaceuticals: The thin end of the boomerang?. Pharmacoeconomics. 1992;1:61–69
  2. Drummond MF. Basing prescription drug payment on economic analysis: The case of Australia. Health Aff (Millwood). 1992;11:191–196
  3. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol. 2007;25:191–195
  4. Colmenero F, Sullivan SD, Palmer JA, et al. Quality of clinical and economic evidence in dossier formulary submissions. Am J Manag Care. 2007;13:401–407
  5. Drummond M, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1995;
  6. Lipscomb JW, Torrance GW. Time preference. In:  Gold MR,  Siegel JE,  Russell LB, et al. editor. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996;p. 214–235
  7. Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In:  Gold MR,  Siegel JE,  Russell LB editor. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996;p. 176–213
  8. Nord E. EuroQol: Health-related quality of life measurement (Valuations of health states by the general public in Norway). Health Policy. 1991;18:25–36
  9. Boyle MH, Furlong W, Feeny D, et al. Reliability of the Health Utilities Index–Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res. 1995;4:249–257
  10. EuroQol—A new facility for the measurement of health-related quality of life (The EuroQol Group). Health Policy. 1990;16:199–208
  11. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med. 2003;163:1637–1641
  12. Neymark N, Adriaenssen I, Gorlia T, et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 2002;11:233–248
  13. O'Sullivan AK, Thompson D, Drummond MF. Collection of health-economic data alongside clinical trials: Is there a future for piggyback evaluations?. Value Health. 2005;8:67–79
  14. Drummond MF, Davies L. Economic analysis alongside clinical trials.Revisiting the methodological issues. Int J Technol Assess Health Care. 1991;7:561–573
  15. Willan AR, O'Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ. 1999;8:203–211
  16. Sonnenberg FA, Beck JR. Markov Models in medical decision making: A practical guide. Med Decis Making. 1993;13:322–338
  17. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419–458
  18. Naimark D, Krahn MD, Naglie G, et al. Primer on medical decision analysis: Part 5—Working with Markov processes. Med Decis Making. 1997;17:152–159
  19. Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: The UK perspective. Eur J Health Econ. 2007;[Epub ahead of print]
  20. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298:629–637
  21. Coupe VM, Berkhof J, Verheijen RH, et al. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG. 2007;114:416–424
  22. Delea TE, Karnon J, Sofrygin O, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer. 2007;7:608–618
  23. Konski A, Sherman E, Krahn M, et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys. 2005;63:788–794
  24. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer (Prostate Patient Outcomes Research Team). JAMA. 1993;269:2650–2658
  25. Hummel S, Paisley S, Morgan A, et al. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: A systematic review. Health Technol Assess 7. 2003;ix-x:1–157iii
  26. Konski A, Watkins-Bruner D, Brereton H, et al. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer. 2006;106:51–57
  27. Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:408–415
  28. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol. 2007;25:3603–3608

PII: S1053-4296(08)00016-7

doi: 10.1016/j.semradonc.2008.01.004

Seminars in Radiation Oncology
Volume 18, Issue 3 , Pages 168-174 , July 2008

Article Tools

* Image Usage & Resolution